Lye Mun Tho

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose–volume relationships and role for inverse planning

Lye Mun Tho, M. Glegg, J R Paterson et al. · International Journal of Radiation Oncology*Biology*Physics · 2006 · 149 citations

Medicine, Oncology, Radiation Oncology +17

Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer

Ross Carruthers, Lye Mun Tho, Jennifer R. Brown et al. · Colorectal Disease · 2012 · 137 citations · Full text

Medicine, Oncology, Surgery +17

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 86 citations · Full text

Medicine, Oncology, Pharmacology +16

Current practices in cancer pain management in Asia: a survey of patients and physicians across 10 countries

Yong‐Chul Kim, Jin Seok Ahn, Maria Minerva P Calimag et al. · Cancer Medicine · 2015 · 79 citations · Full text

Medicine, Oncology, Cancer Pain Management +13